Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Akero Therapeutics Inc shares valued at $597,326 were sold by Young Jonathan on Aug 12 ’25. At $47.79 per share, Young Jonathan sold 12,500 shares. The insider’s holdings dropped to 197,484 shares worth approximately $9.89 million following the completion of this transaction.
Also, Cheng Andrew sold 30,000 shares, netting a total of over 1,457,596 in proceeds. Following the sale of shares at $48.59 each, the insider now holds 490,757 shares.
Before that, Henderson Jane had sold 3,000 shares from its account. In a trade valued at $142,371, the Director traded Akero Therapeutics Inc shares for $47.46 each. Upon closing the transaction, the insider’s holdings decreased to 3,000 shares, worth approximately $0.47 million.
As published in their initiating research note from TD Cowen on August 04, 2025, Akero Therapeutics Inc [AKRO] has been a Buy and the price target has been revised to $76. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late January. As of January 27, 2025, H.C. Wainwright has reiterated its “Buy” rating for AKRO. Earlier on November 18, 2024, Citigroup initiated its rating. Their recommendation was “a Buy” for AKRO stock.
Analyzing AKRO Stock Performance
On last trading session, Akero Therapeutics Inc [NASDAQ: AKRO] rose 3.68% to $50.09. The stock’s lowest price that day was $47.31, but it reached a high of $50.19 in the same session. During the last five days, there has been a drop of approximately -0.71%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 107.07%. Shares of the company reached a 52-week high of $58.40 on 01/27/25 and a 52-week low of $21.34 on 01/14/25.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
According to the 24-hour chart, there is a support level at 48.20, which, if violated, would cause prices to drop to 46.32. In the upper region, resistance lies at 51.08. The next price resistance is at 52.08. RSI (Relative Strength Index) is 49.74 on the 14-day chart, showing neutral technical sentiment.
Is Akero Therapeutics Inc subject to short interest?
Stocks of Akero Therapeutics Inc saw a sharp steep in short interest on 2025-07-31 dropping by -0.94 million shares to 8.12 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 9.06 million shares. A decline of -11.56% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.56 of the overall float, the days-to-cover ratio (short ratio) decline to 8.56.
Which companies own the most shares of Akero Therapeutics Inc (AKRO)?
In terms of Akero Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 45 in the next 12 months, down nearly -6.85% from the previous closing price of $48.31. Analysts anticipate Akero Therapeutics Inc stock to reach 56 by 2025, with the lowest price target being 38. In spite of this, 4 analysts ranked Akero Therapeutics Inc stock as Buy at the end of 2025. On April 22, 2024, BofA Securities assigned a price target of “a Neutral” to the stock and resumed coverage with a $30.
